IMR Press / CEOG / Volume 23 / Issue 4 / pii/1996045

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research

GnRH analogs in treating uterine Jeiomyornata and endometriosis

Show Less
1 2nd Department of Obstetrics & Gynecology, Medical University of Gdansk, Poland
Clin. Exp. Obstet. Gynecol. 1996, 23(4), 214–219;
Published: 10 December 1996
Abstract

The results of hormonal examinations, measurements of dimensions of the uterus and leiomyomas, body weight, and also frequency of incurred climacteric signs in patients treated with Decapeptyl Depot 3.75 mg for three months are reported. Subjects consisted of 12 women, among whom nine were treated for leiomyomas and four for endometriosis (one patient also had leiomyomas). Based on examinations carried out, the biggest decrease of the uterus and leiomyomas was 13-17% observed just after two doses of analog, though after the end of treatment the dimensions of the uterus slowly increased. Therefore, 2-month therapy could be used successfully as preparation for further conservative surgical treatment. Significant increase of body weight in treated patients was not observed. In women with endometriosis pain symptoms in the hypogastric area and dyspareunia regressed during treatment and at the end were not observed. The disadvantages of therapy with Decapeptyl Depot 3.75 was the rapid occurrence of symptoms-climacteric signs, especially hot flashes-which were badly tolerated by patients. All these symptoms almost totally regressed one month after ending therapy.

Keywords
a-GnRH
Uterine myoma
Endometriosis
Share
Back to top